



Pirouette Medical, Inc. (the “Company”) a Delaware Corporation

Financial Statements (audited) and
Independent Auditor’s Report

Years ended December 31, 2024 & 2023



Independent Auditor's Report

To Management
Pirouette Medical, Inc.

We have audited the accompanying balance sheets of Pirouette Medical, Inc. as of December 31, 2024 and 2023, and the related statements of operations and comprehensive loss, statements of changes in stockholders' equity (deficit), and the statements of cash flows for the years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.

Opinion

We believe that our audits provide a reasonable basis for our opinion. In our opinion, the financial statements referred to above, present fairly, in all material respects, the financial position of The Pirouette Medical, Inc. as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America

Going Concern

As discussed in Note 8, certain conditions indicate that the Company may be unable to continue as a going concern. The accompanying financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. Management has evaluated these conditions and plans to generate revenues and raise capital as needed to satisfy its capital needs. Our opinion is not modified with respect to this matter.

Vince Mongio, CPA, EA, CIA, CFE, MACC
Miami, FL
March 27th, 2024

Vincenzo Mongio

PIROUETTE MEDICAL, INC.
BALANCE SHEETS (AUDITED)

| | <u>December 31, 2024</u> | <u>December 31, 2023</u> |
|---|---------------------------------|---------------------------------|
| Assets | | |
| Current Assets: | | |
| Cash and Cash Equivalents | \$ 1,610,924 | \$ 2,094,498 |
| Prepaid Expenses | 81,786 | 252,077 |
| Other Receivables | 95,117 | 53,516 |
| Total Current Assets | <u>1,787,827</u> | <u>2,400,091</u> |
| Non Current Assets: | | |
| Furniture & Equipment, Machinery, Cleanroom, and Leasehold Improvements, Net of Accumulated Depreciation | 1,141,952 | 1,168,766 |
| Software, Patents, Trademarks, Net of Accumulated | 541,572 | 511,236 |
| Right of Use Asset - Operating Lease, Net of Accumulated Amortization | 361,649 | 378,606 |
| Security Deposits | 45,452 | 45,452 |
| Total Non Current Assets | <u>2,090,625</u> | <u>2,104,060</u> |
| Total Assets | <u>\$ 3,878,452</u> | <u>\$ 4,504,151</u> |
| Liabilities and Stockholders' Equity (Deficit) | | |
| Liabilities | | |
| Current Liabilities: | | |
| Accounts Payable | \$ 13,258 | \$ 14,105 |
| Accrued Expenses | 155,846 | 65,466 |
| Payroll Liabilities | 226,865 | 34,360 |
| Short-term Lease Liability - Operating Lease | 101,361 | 76,530 |
| Total Current Liabilities | <u>497,330</u> | <u>190,461</u> |
| Non Current Liabilities: | | |
| Future Equity Obligations (SAFE Notes), net of Offering Costs | 7,121,085 | 3,966,200 |
| Long-term Lease Liability - Operating Lease | 267,784 | 305,234 |
| Total Non Current Liabilities | <u>7,388,869</u> | <u>4,271,434</u> |
| Total Liabilities | <u>7,886,199</u> | <u>4,461,895</u> |
| Commitments and Contingencies (Note 4) | | |
| Stockholders' Equity (Deficit) | | |
| Series A1 Preferred Stock, Voting, \$0.00001 Par Value - 1,288,640 Shares Authorized, 1,288,640 Shares Issued and Outstanding as of December 31, 2024 | 13 | 13 |
| Series A2 Preferred Stock, Voting, \$0.00001 Par Value - 468,793 Shares Authorized, 468,793 Shares Issued and Outstanding as of December 31, 2024 | 5 | 5 |
| Series A3 Preferred Stock, Voting, \$0.00001 Par Value - 1,587,054 Shares Authorized, 1,587,054 Shares Issued and Outstanding as of December 31, 2024 | 16 | 16 |

PIROUETTE MEDICAL, INC.
BALANCE SHEETS (AUDITED) (CONTINUED)

| | <u>December 31, 2024</u> | <u>December 31, 2023</u> |
|---|---------------------------------|---------------------------------|
| Series A4 Preferred Stock, Voting, \$0.00001 Par Value - 1,093,863 Shares Authorized, 1,093,863 Shares Issued and Outstanding as of December 31, 2024 | 11 | 11 |
| Series A5 Preferred Stock, Voting, \$0.00001 Par Value - | 51 | 51 |
| Common Stock, Voting, \$0.00001 Par Value - 21,000,000 | - | - |
| Additional Paid In Capital | 9,853,397 | 9,853,397 |
| Accumulated Deficit | <u>(13,861,239)</u> | <u>(9,811,236)</u> |
| Total Stockholders' Equity (Deficit) | <u>(4,007,747)</u> | <u>42,256</u> |
| Total Liabilities and Stockholders' Equity (Deficit) | \$ <u>3,878,452</u> | \$ <u>4,504,151</u> |

PIROUETTE MEDICAL, INC.
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (AUDITED)

| | For the Years Ended | |
|--|---------------------------------|---------------------------------|
| | <u>December 31, 2024</u> | <u>December 31, 2023</u> |
| Revenues: | | |
| | \$ - | \$ - |
| Total Revenues | - | - |
| Cost of Sales | | |
| Cost of Sales | \$ - | \$ - |
| Total Cost of Sales | - | - |
| Gross Profit | - | - |
| Operating Expenses: | | |
| Legal and Professional | \$ 181,692 | \$ 263,444 |
| General and Administrative | 2,187,854 | 1,912,159 |
| Research and Development | 1,831,135 | 1,360,722 |
| Operating Lease Expense | 111,692 | 104,339 |
| Depreciation | 115,037 | 73,960 |
| Amortization - Patents | 29,773 | 20,383 |
| Total Operating Expenses | \$ 4,457,183 | \$ 3,735,007 |
| Other (Income) Expense: | | |
| Grant Income | \$ (387,155) | \$ (84,106) |
| Interest Income | (25,127) | (51,703) |
| Loss on Asset Disposal | 7,162 | - |
| Other Income | (2,060) | (2,182) |
| Total Other (Income) Expense | \$ (407,180) | \$ (137,991) |
| Loss from Continuing Operations Before Income Taxes | \$ (4,050,003) | \$ (3,597,016) |
| Provision for Income Taxes | - | - |
| Net Loss | \$ (4,050,003) | \$ (3,597,016) |

PIROUETTE MEDICAL, INC.
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

| | Preferred Stock | | | | | | | | | |
|------------------------------|-----------------|--------|-----------|--------|-----------|--------|-----------|--------|-----------|--------|
| | Series A1 | | Series A2 | | Series A3 | | Series A4 | | Series A5 | |
| | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount |
| Balance on January 1, 2023 | 1,288,640 | \$ 13 | 468,793 | \$ 5 | 1,587,054 | \$ 16 | 1,093,863 | \$ 11 | 5,100,888 | \$ 51 |
| Net Loss | - | - | - | - | - | - | - | - | - | - |
| Balance on December 31, 2023 | 1,288,640 | \$ 13 | 468,793 | \$ 5 | 1,587,054 | \$ 16 | 1,093,863 | \$ 11 | 5,100,888 | \$ 51 |
| Net Loss | - | - | - | - | - | - | - | - | - | - |
| Balance on December 31, 2024 | 1,288,640 | \$ 13 | 468,793 | \$ 5 | 1,587,054 | \$ 16 | 1,093,863 | \$ 11 | 5,100,888 | \$ 51 |

PIROUETTE MEDICAL, INC.
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (CONTINUED)
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

| | Common Stock | | Additional Paid-In | | Accumulated | Total |
|-------------------------------------|-------------------|-------------|---------------------|------------------------|-------------|--------------------|
| | Shares | Amount | Capital | | Deficit | Stockholders' |
| | | | | | Deficit | Deficit |
| Balance on January 1, 2023 | 10,000,000 | \$ - | \$ 9,853,397 | \$ (6,214,220) | \$ | 3,639,272 |
| Net Loss | - | - | - | (3,597,016) | | (3,597,016) |
| Balance on December 31, 2023 | 10,000,000 | \$ - | \$ 9,853,397 | \$ (9,811,236) | \$ | 42,256 |
| Net Loss | - | - | - | (4,050,003) | | (4,050,003) |
| Balance on December 31, 2024 | 10,000,000 | \$ - | \$ 9,853,397 | \$ (13,861,239) | \$ | (4,007,747) |

PIROUETTE MEDICAL, INC.
STATEMENTS OF CASH FLOWS (AUDITED)

| | For the Years Ended December 31, | |
|--|---|-----------------------|
| | <u>2024</u> | <u>2023</u> |
| OPERATING ACTIVITIES | | |
| Net Loss | \$ (4,050,003) | \$ (3,597,016) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | | |
| Depreciation | \$ 115,037 | \$ 73,960 |
| Amortization - Patents | 29,773 | 20,383 |
| Operating Lease Expense | 4,338 | 3,158 |
| Loss on Disposal of R&D Equipment | - | - |
| Loss on Disposal of Software Asset | - | 3,491 |
| Changes in operating assets and liabilities: | | |
| Accounts Payable | (847) | (185) |
| Accrued Expenses | 90,380 | (38,300) |
| Payroll Liabilities | 192,505 | 15,654 |
| Prepaid Expenses | 170,291 | (190,519) |
| Other Receivables | (41,601) | (34,259) |
| Security Deposits | - | (43,786) |
| Net Cash Flows provided by (used in) Operating Activities | \$ (3,490,127) | \$ (3,787,419) |
| INVESTING ACTIVITIES | | |
| Acquisition of Fixed Assets | \$ (88,223) | \$ (951,657) |
| Acquisition of Intangible Assets | (60,109) | (63,433) |
| Net Cash Flows provided by (used in) Investing Activities | \$ (148,332) | \$ (1,015,090) |
| FINANCING ACTIVITIES | | |
| Future Equity Obligations (SAFE Notes), net of Offering Costs | \$ 3,154,885 | \$ 684,700 |
| Net Cash Flows provided by (used in) Financing Activities | \$ 3,154,885 | \$ 684,700 |
| Net change in cash | \$ (483,574) | \$ (4,117,809) |
| Cash and Equivalents at the beginning of the year | 2,094,498 | 6,212,307 |
| Cash and Equivalents at the end of the year | \$ 1,610,924 | \$ 2,094,498 |

Pirouette Medical, Inc.
Notes to the Audited Financial Statements
December 31st, 2024 and 2023
SUSD

NOTE 1 – ORGANIZATION AND NATURE OF ACTIVITIES

Pirouette Medical, Inc. (“the Company”) was formed in Delaware on May 26th, 2021. Pirouette Medical LLC was formed in Delaware on June 8th, 2017. The Company was formed as a result of Pirouette Medical LLC being converted from an LLC to C-Corp on May 26th, 2021. The same EIN was retained. The Company is a cutting-edge pharmaceutical business that is changing the ways drugs are delivered and revolutionizing healthcare accessibility. It plans to earn revenue by selling its innovative drug-delivery communication devices (drug-device) and associated products through various pathways such as in bulk to wholesale distributors or direct to consumers. Additional revenue pathways exist such as licensing the delivery system to drug manufacturers. The Company's customers will be located first in the United States, upon FDA approval, and then spread to a global market, pending subsequent approvals. Currently, the Company is in the design and development phase of their initial products, has not attained FDA approval, and is thus not revenue generating.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Our financial statements are prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Our fiscal year ends on December 31. The Company has no interest in variable interest entities and no predecessor entities.

Use of Estimates and Assumptions

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents include all cash balances, and highly liquid investments with maturities of three months or less when purchased. The Company does not have any restrictions on its cash balance.

Fair Value of Financial Instruments

ASC 820 “*Fair Value Measurements and Disclosures*” establishes a three-tier fair value hierarchy, which prioritizes the inputs in measuring fair value. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market.

These tiers include:

Level 1: defined as observable inputs such as quoted prices in active markets;

Level 2: defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

Level 3: defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Pirouette Medical, Inc.
Notes to the Audited Financial Statements
December 31st, 2024 and 2023
SUSD

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Concentrations of Credit Risks

The Company's financial instruments that are exposed to concentrations of credit risk primarily consist of its cash and cash equivalents. The Company places its cash and cash equivalents with financial institutions of high credit worthiness. The Company's management assesses the financial strength and credit worthiness of any parties to which it extends funds, and as such, it believes that any associated credit risk exposures are limited.

As of December 31, 2024 and 2023, the Company's total ending cash balance within its main operating account was \$1,608,355 and \$2,008,428, respectively. This cash is spread amongst multiple financial institutions with the standard deposit insurance coverage limit of \$250,000. The Company does not maintain a balance greater than \$250,000 in any one single institution, ensuring sufficient coverage of its operating cash.

Revenue Recognition

The Company recognizes revenue from the sale of products and services in accordance with ASC 606, "Revenue Recognition" following the five steps procedure:

- Step 1: Identify the contract(s) with customers
- Step 2: Identify the performance obligations in the contract
- Step 3: Determine the transaction price
- Step 4: Allocate the transaction price to performance obligations
- Step 5: Recognize revenue when or as performance obligations are satisfied

The Company will identify and analyze its performance obligations with respect to customer contracts once the first contract is signed.

Property and Equipment

Property and equipment are recorded at cost. Expenditures for renewals and improvements that significantly add to the productive capacity or extend the useful life of an asset are capitalized. Expenditures for maintenance and repairs are charged to expense. When equipment is retired or sold, the cost and related accumulated depreciation are eliminated from the accounts and the resultant gain or loss is reflected in income. Depreciation is provided using the straight-line method, based on useful lives of the assets.

The Company reviews the carrying value of property and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition, and other economic factors. Based on this assessment there was no impairment for December 31, 2024 and 2023.

Pirouette Medical, Inc.
Notes to the Audited Financial Statements
December 31st, 2024 and 2023
\$USD

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Property and Equipment (Continued)

A summary of the Company's property and equipment, along with their annual activity, is provided below:

| Property Type | Useful Life in Years | Cost | Accumulated Depreciation | Disposals | Book Value as of 12/31/24 |
|------------------------|----------------------|------------------|--------------------------|-----------|---------------------------|
| Furniture & Equipment | 5-10 | 108,129 | (24,890) | - | 83,239 |
| Machinery | 5-15 | 890,169 | (139,873) | - | 750,296 |
| Leasehold Improvements | 10 | 341,040 | (32,623) | - | 308,417 |
| Grand Total | - | 1,339,338 | (197,386) | - | 1,141,952 |

| 2024 | | | |
|------------------------|---------------|----------------------|----------------|
| Property Type | New Additions | Depreciation Expense | Disposals |
| Furniture & Equipment | 33,054 | (14,542) | - |
| Machinery | 43,450 | (74,587) | (7,162) |
| Leasehold Improvements | 11,719 | (25,908) | - |
| Grand Total | 88,223 | (115,037) | (7,162) |

| 2023 | | | |
|------------------------|----------------|----------------------|-----------|
| Property Type | New Additions | Depreciation Expense | Disposals |
| Furniture & Equipment | 49,303 | (7,515) | - |
| Machinery | 573,032 | (59,730) | - |
| Leasehold Improvements | 329,322 | (6,715) | - |
| Grand Total | 951,657 | (73,960) | - |

Intangible Assets

The Company's intangible assets consist of CAD software, patents, and trademarks. They are recorded at cost less accumulated amortization and impairment losses on a systematic basis over their respective useful lives.

A summary of the Company's intangible assets, along with their annual activity, is provided below:

| Property Type | Useful Life in Years | Cost | Accumulated Amortization | Disposals | Book Value as of 12/31/24 |
|--------------------|----------------------|----------------|--------------------------|-----------|---------------------------|
| Patents | 15 -19 | 544,276 | (87,268) | - | 457,008 |
| Trademarks | Indefinite | 84,564 | - | - | 84,564 |
| Grand Total | - | 628,840 | (87,268) | - | 541,572 |

Pirouette Medical, Inc.
Notes to the Audited Financial Statements
December 31st, 2024 and 2023
\$USD

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Intangible Assets (Continued)

| 2024 | | | |
|----------------------|----------------------|-----------------------------|------------------|
| Property Type | New Additions | Amortization Expense | Disposals |
| Patents | 57,816 | (29,773) | - |
| Trademarks | 2,293 | - | - |
| Grand Total | 60,109 | (29,773) | - |

| 2023 | | | |
|----------------------|----------------------|-----------------------------|------------------|
| Property Type | New Additions | Amortization Expense | Disposals |
| Software | - | - | (3,512) |
| Patents | 61,797 | (20,383) | - |
| Trademarks | 1,637 | - | - |
| Grand Total | 63,434 | (20,383) | (3,512) |

Accounts Receivable

Trade receivables due from customers are uncollateralized customer obligations due under normal trade terms. Trade receivables are stated at the amount billed to the customer. Payments of trade receivables are allocated to the specific invoices identified on the customer's remittance advice or, if unspecified, are applied to the earliest unpaid invoices. Payments are generally collected upfront, but some of the merchants that products are sold through have a delay between collecting from the customer and sending to the Company.

The Company estimates an allowance for doubtful accounts based upon an evaluation of the current status of receivables, historical experience, and other factors as necessary. It is reasonably possible that the Company's estimate of the allowance for doubtful accounts will change.

General and Administrative

General and administrative expenses consist of payroll and related expenses for employees and independent contractors involved in general corporate functions, including finance, business development, and other miscellaneous expenses. Material operating expenses such as legal, accounting, and other professional services have been presented separately from general and administrative.

Equity-Based Compensation

In 2021, the Company adopted its 2021 Equity Incentive Plan ("the Plan") for the purposes of attracting and retaining key personnel. A total of 309,278 shares of Common Stock have been allocated towards this Plan to be awarded as Stock Options, Stock Appreciation Rights, Restricted Stock, and Restricted Stock Units. In 2023, a total of 59,550 Stock Options were granted that vest in accordance with the following schedule: 25% upon the one-year anniversary of the vesting commencement date, followed by 36-equal monthly installments until fully vested. These Stock Options have an exercise price that ranges from \$0.19 - \$0.24 per share.

Pirouette Medical, Inc.
Notes to the Audited Financial Statements
December 31st, 2024 and 2023
SUSD

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Equity-Based Compensation (Continued)

The Company accounts for stock options issued to employees under ASC 718 (Stock Compensation). Under ASC 718, share-based compensation cost to employees is measured at the grant date, based on the estimated fair value of the award, and is recognized as an item of expense ratably over the employee's requisite vesting period. The Company has elected early adoption of ASU 2018-07, which permits measurement of stock options at their intrinsic value, instead of their fair value. An option's intrinsic value is defined as the amount by which the fair value of the underlying stock exceeds the exercise price of an option. In certain cases, this means that option compensation granted by the Company may have an intrinsic value of \$0.

The Company measures compensation expense for its non-employee stock-based compensation under ASC 505 (Equity). The fair value of the option issued or committed to be issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company's common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty's performance is complete. The fair value of the equity instrument is charged directly to expense and credited to additional paid-in capital.

There is not a viable market for the Company's common stock to determine its fair value, therefore management is required to estimate the fair value to be utilized in determining stock-based compensation costs. In estimating the fair value, management considers recent sales of its common stock to independent qualified investors, placement agents' assessments of the underlying common shares relating to our sale of preferred stock and validation by independent fair value experts. Considerable management judgment is necessary to estimate the fair value. Accordingly, actual results could vary significantly from management's estimates. Management has concluded that the estimated fair value of the Company's stock and corresponding expense is negligible.

The following is an analysis of options to purchase shares of the Company's Common Stock issued and outstanding:

| | Total Options | Weighted Average Exercise Price | Weighted Average Intrinsic Value |
|--|--------------------------|--|---|
| Total options outstanding, January 1, 2023 | - | \$ - | \$ - |
| Granted | 59,550 | \$0.22 | \$ - |
| Exercised | - | \$ - | \$ - |
| Expired/cancelled | - | | |
| Total options outstanding, December 31, 2023 | 59,550 | \$0.22 | \$ - |
| Granted | - | \$ - | \$ - |
| Exercised | - | \$ - | \$ - |
| Expired/cancelled | (35,358) | \$0.22 | |
| Total options outstanding, December 31, 2024 | 24,192 | \$0.22 | \$ - |
| Options exercisable, December 31, 2024 | 12,611 | \$0.20 | \$ - |

Pirouette Medical, Inc.
Notes to the Audited Financial Statements
December 31st, 2024 and 2023
\$USD

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Equity-Based Compensation (Continued)

| | Nonvested Options | Weighted Average Fair Value |
|--------------------------------------|------------------------------|--|
| Nonvested options, January 1, 2023 | - | \$- |
| Granted | 59,550 | \$0.22 |
| Vested | (2,688) | \$0.19 |
| Forfeited | - | \$- |
| Nonvested options, December 31, 2023 | 56,862 | \$0.22 |
| Granted | - | \$- |
| Vested | (9,923) | \$0.20 |
| Forfeited | (35,358) | \$0.22 |
| Nonvested options, December 31, 2024 | 11,581 | \$0.22 |

Income Taxes

The Company is subject to corporate income and state income taxes in the state it does business. We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. We record uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company does not have any uncertain tax provisions. The Company's primary tax jurisdictions are the United States. The Company's primary deferred tax assets are its net operating loss (NOL) carryforwards which approximates its retained earnings as of the date of these financials. A deferred tax asset as a result of NOLs have not been recognized due to the uncertainty of future positive taxable income to utilize the NOL. The Company is no longer subject to U.S. federal, state and local, tax examinations by tax authorities for years before 2019.

As of the date of these financials, the Company has filed its tax returns for all preceding years except for 2024 and is in the process of doing so.

Recent Accounting Pronouncements

The FASB issues ASUs to amend the authoritative literature in ASC. There have been a number of ASUs to date that amend the original text of ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to us or (iv) are not expected to have a significant impact on our financial statements.

Pirouette Medical, Inc.
Notes to the Audited Financial Statements
December 31st, 2024 and 2023
SUSD

NOTE 3 – RELATED PARTY TRANSACTIONS

The Company follows ASC 850, “Related Party Disclosures,” for the identification of related parties and disclosure of related party transactions. No transactions require disclosure.

NOTE 4 – COMMITMENTS, CONTINGENCIES, COMPLIANCE WITH LAWS AND REGULATIONS

We are currently not involved with or know of any pending or threatening litigation against the Company or any of its officers. Further, the Company is currently complying with all relevant laws and regulations.

Operating Leases

The Company accounts for its lease in accordance with ASC 842 (Leases). Under ASC 842, leases are identified on the Balance Sheet as right-of-use assets with corresponding liabilities. The right-of-use asset is amortized over its operating cycle using the effective interest rate at the time of lease inception.

The Company leases two commercial real estate facilities as part of its operations. In May 2023, the Company signed a 5-year lease agreement with monthly payments of approximately \$7,517 to expand its facility into the adjacent high-bay spaces to accommodate the growing team as well as the manufacturing and testing of devices.

In October of 2024, the Company amended its month-to-month lease for one of its locations and entered into a three year and eight months lease, terminating in May of 2028. Monthly payments are \$1,775 per month with an annual increase that is based on the consumer price index for all urban consumers applicable to the Boston area and shall not increase more than 3% per year.

Below are the weighted average interest rates and future minimum lease payments:

FASB ASC 842 Footnote

| | Year Ended |
|-------------------------|-------------------|
| Lease expense | December 31, 2024 |
| Operating lease expense | 111,692 |
| Variable lease expense | - |
| Total | 111,692 |

Other Information

| | |
|--|--------|
| Cash paid for amounts included in the measurement of lease liabilities | |
| Operating cash flows from finance leases (i.e. Interest) | |
| Operating cash flows from operating leases | 94,427 |
| ROU assets obtained in exchange for new operating lease liabilities | 75,024 |
| Weighted-average remaining lease term in years for operating leases | 3.41 |
| Weighted-average discount rate for operating leases | 4.50% |

Maturity Analysis

Operating

Pirouette Medical, Inc.
Notes to the Audited Financial Statements
December 31st, 2024 and 2023
\$USD

**NOTE 4 – COMMITMENTS, CONTINGENCIES, COMPLIANCE WITH LAWS AND REGULATIONS
(CONTINUED)**

Operating Leases (Continued)

| | |
|--------------------------------------|----------------|
| 2025-12 | 113,233 |
| 2026-12 | 116,629 |
| 2027-12 | 120,128 |
| 2028-12 | 50,764 |
| Thereafter | - |
| Total undiscounted cash flows | 400,754 |
| Less: present value discount | (31,609) |
| Total lease liabilities | 369,145 |

Grants

The Company received the final Notice of Award (NoA) in August 2023 for a Small Business Innovation Research (SBIR) Grant from the National Institute of Health (NIH) and National Institute on Drug Abuse (NIDA). The \$326,500 grant supports filling our patented auto-injector with Naloxone HCl, USP for emergency treatment of opioid overdoses, addressing the opioid epidemic that is costing approximately 200 lives daily.

In February 2024, the Company was accepted into the NIH/NIDA I-Core program. This two-month program helped us confirm product-market fit, refine the broader commercialization plan, determine if there is a community need for a 3rd dose strength, and connect with early payors for market launch, and includes a \$55,000 grant.

In May 2024, the Company received a final NoA Phase I Grant from the NIH with an administrative supplement of \$97,580 in addition to the initial \$326,500. This affirms the technical merit and commercial potential of our research.

In total, the Company Grant awards from the NIH amount to \$479,080. These funds supported the application in 2024.

NOTE 5 – LIABILITIES AND DEBT

Future Equity Obligations - Simple Agreements for Future Equity (SAFE)

From 2017 through the period ending December 31, 2021, the Company entered into numerous SAFE agreements with third parties for total proceeds of \$4,450,000. The SAFE agreements had no maturity date and accrued no interest. Following the occurrence of an equity financing event, the agreements converted in August 2021 into various shares of Preferred Stock in an amount determined by one of the four calculations, depending on the applicable SAFE agreement:

- i. The SAFE Purchase Price divided by the lesser of (a) the price-per-share of the Preferred Stock sold during the equity financing event, multiplied by the Discount Rate of 75% - 80%, or (b) the price-per-share equal to the Valuation Cap of \$9M divided by the then-issued and outstanding shares of the Company's Capital Stock, subject to conversions and exclusions in accordance with the SAFE agreement.
- ii. The SAFE Purchase Price divided by the price-per-share of the Preferred Stock sold during the equity financing event, multiplied by the Discount Rate of 75% - 80%.
- iii. The SAFE Purchase Price divided by either (a) the price-per-share of the Preferred Stock sold during the equity financing event, or (b) the price-per-share equal to the Valuation Cap of \$15M divided by the

Pirouette Medical, Inc.
Notes to the Audited Financial Statements
December 31st, 2024 and 2023
\$USD

NOTE 5 – LIABILITIES AND DEBT (CONTINUED)

Future Equity Obligations - Simple Agreements for Future Equity (SAFE) (Continued)

- then-issued and outstanding shares of the Company's Capital Stock, subject to conversions and exclusions in accordance with the SAFE agreement.
- iv. The then-issued and outstanding shares of the Company's Capital Stock, subject to conversions and exclusions in accordance with the SAFE agreement, multiplied by 7.00%.

The SAFE agreements disclosed above have converted into the following series of Preferred Stock:

- i. \$1,125,000 converted into 1,288,640 shares of Series A1 Preferred Stock.
- ii. \$450,000 converted into 468,793 shares of Series A2 Preferred Stock.
- iii. \$1,625,000 converted into 1,587,054 shares of Series A3 Preferred Stock.
- iv. \$125,000 converted into 1,093,863 shares of Series A4 Preferred Stock.
- v. \$1,125,000 converted into 878,989 shares of Series A5 Preferred Stock.

From 2022 through the period ending December 31, 2024, the Company entered into numerous SAFE agreements with third parties for total proceeds of \$7,440,005. The offering costs associated with these SAFE agreements amounted to \$318,920 as of December 31, 2024. The SAFE agreements have no maturity date and bear no interest. Upon the occurrence of an equity financing event, the agreements provide the right of the investor to future equity in the form of the same series of Preferred Stock in an amount equal to the SAFE Purchase Price divided by the lesser of (i) the price-per-share of the Preferred Stock sold during the equity financing event, multiplied by the Discount Rate of 80%, and (ii) the price-per-share equal to the Valuation Cap of \$55M divided by the then-issued and outstanding shares of the Company's Capital Stock, subject to conversions and exclusions in accordance with the SAFE agreement. Alternatively, upon the occurrence of a liquidity event, the agreements provide the right of the investor to a portion of the proceeds equal to the greater of (i) the SAFE Purchase Price, or (b) the amount payable on the number of shares of Common Stock equal to the SAFE Purchase Price divided by the price-per-share equal to (x) the Valuation Cap of \$55M divided by (y) the then-issued and outstanding shares of the Company's Capital Stock, subject to conversions and exclusions in accordance with the SAFE agreements. Furthermore, the SAFE agreements provide the right of the investor to receive dividends when and if declared by the Board of Directors in an amount equal to the declared dividend multiplied by the quotient of the SAFE Purchase Price divided by the price-per-share equal to (x) the Valuation Cap of \$55M divided by (y) the then-issued and outstanding shares of the Company's Capital Stock, subject to conversions and exclusions in accordance with the SAFE agreements. No such events have occurred as of the date of these financials.

Debt Summary

| Debt Instrument Name | Principal Amount | Interest Rate | Maturity Date | For the Year Ended December 2024 | | | | For the Year Ended December 2023 | | | |
|----------------------|------------------|---------------|---------------|----------------------------------|---------------------|--------------------|------------------|----------------------------------|---------------------|--------------------|------------------|
| | | | | Current Portion | Non-Current Portion | Total Indebtedness | Accrued Interest | Current Portion | Non-Current Portion | Total Indebtedness | Accrued Interest |
| SAFE Notes | 7,440,005 | N/A | N/A | - | 7,440,005 | 7,440,005 | - | - | 3,966,200 | 3,966,200 | - |
| Total | | | | - | 7,440,005 | 7,440,005 | - | - | 3,966,200 | 3,966,200 | - |

Debt Principal Maturities 5 Years Subsequent to 2024

| Year | Amount |
|------------|--------|
| 2025 | - |
| 2026 | - |
| 2027 | - |
| 2028 | - |
| 2029 | - |
| Thereafter | - |

Pirouette Medical, Inc.
Notes to the Audited Financial Statements
December 31st, 2024 and 2023
SUSD

NOTE 5 – LIABILITIES AND DEBT (CONTINUED)

*The SAFE Notes mature during a qualified equity financing or liquidity event which can occur in any year.

NOTE 6 – EQUITY

Upon its initial incorporation in May 2021, the Company authorized 20,000,000 shares of Common Stock with a par value of \$0.00001 per share. In August 2021, the Company amended its Article of Incorporation to increase the number of authorized shares of Common Stock to 20,500,000 with the same par value, and to authorize 9,223,985 shares of Preferred Stock with a par value of \$0.00001 per share. In October 2021, the Company amended its Articles of Incorporation a second time to increase its authorized shares of both Common and Preferred Stock to the respective amounts of 21,000,000 and 9,692,782 shares with par values of \$0.00001 per share.

A total of 10,000,000 shares of Common Stock were issued and outstanding as of December 31, 2024 and 2023.

Voting: Common Shareholders are entitled to one vote per share.

Dividends: Common Shareholders are entitled to receive dividends when and if declared by the Board of Directors.

A total of 9,539,238 shares of Preferred Stock were issued and outstanding as of December 31, 2024. These shares are made up of the following designated series of Preferred Stock:

- (i) 1,288,640 shares of Series A1 Preferred Stock, all issued and outstanding as of December 31, 2023
- (ii) 468,793 shares of Series A2 Preferred Stock, all issued and outstanding as of December 31, 2023
- (iii) 1,587,054 shares of Series A3 Preferred Stock, all issued and outstanding as of December 31, 2023
- (iv) 1,093,863 shares of Series A4 Preferred Stock, all issued and outstanding as of December 31, 2023
- (v) 5,254,432 shares of Series A 5 Preferred Stock, of which 5,100,888 were issued and outstanding as of December 31, 2023.

*Please see “Note 5” regarding the conversion of SAFE agreements into various series of Preferred Stock.

Voting: Preferred Shareholders have 1 vote for every share of Common Stock they could own if converted.

Dividends: Preferred Shareholders are entitled to receive dividends when and if declared by the Board of Directors on a pari passu basis according to the number of shares of Common Stock held by such holders. For this purpose, each Preferred Shareholder will be treated as holding the greatest whole number of shares of Common Stock then issuable upon conversion of all shares of Preferred Stock. Dividends on Preferred Stock are in preference to and prior to any payment of any dividend on Common Stock and are not cumulative. No dividends had been declared as of December 31, 2024 and 2023.

Conversion: Preferred Shareholders have the right to convert shares into Common Stock at a rate of 1-to-1 at the discretion of the shareholder, or automatically during change of control events.

Liquidation Preference: In the event of any liquidation, dissolution or winding up of the Company, the holders of Preferred Stock are entitled to receive prior to, and in preference to, any distribution to the Common Shareholders.

NOTE 7 – SUBSEQUENT EVENTS

The Company has evaluated events subsequent to December 31, 2024 to assess the need for potential recognition or disclosure in this report. Such events were evaluated through April 3, 2025, the date these financial statements were available to be issued.

The Company has changed the official name of Pirouette Medical Inc. to Pirouette Pharma Inc. effective January 17, 2025. At Pirouette, the Company is developing “combination products” (device + therapy) as a complete solution.

Pirouette Medical, Inc.
Notes to the Audited Financial Statements
December 31st, 2024 and 2023
SUSD

NOTE 7 – SUBSEQUENT EVENTS (CONTINUED)

Therefore, the Company is technically a pharmaceutical company, not a medical device company (even though that is the focus of their R&D currently). As a combination product with the acting agent being the drug product, the lead review division of their products at the FDA is CDER, so they are on the drug side which also feeds into them truly being a pharma company. The FDA doesn't consider their products to be medical devices, but rather drugs.

Through April 3rd, 2025, the Company raised an additional \$3,237,576 in investment capital through the issuance of additional SAFE agreements.

NOTE 8 – GOING CONCERN

The accompanying balance sheet has been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The entity has not commenced principal operations and will likely realize losses prior to generating positive working capital for an unknown period of time. During the next twelve months, the Company intends to finance its operations with funds from a crowdfunding campaign and other potential investment capital opportunities. The Company's ability to continue as a going concern in the next twelve months following the date the financial statements were available to be issued is dependent upon its ability to produce revenues and/or obtain financing sufficient to meet current and future obligations and deploy such to produce profitable operating results. Management has evaluated these conditions and plans to generate revenues and raise capital as needed to satisfy its capital needs. No assurance can be given that the Company will be successful in these efforts. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities.